HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Consumer Health Regulation: Before Warning, Recall For Supplement With COVID-19 Label Claim

Executive Summary

Until FDA on 23 June posted report about Golden Nutrition Inc.’s herbal supplement, violative COVID-19 claims had been found online and in advertising through other channels. Other consumer health recalls in US include more than 2.5m bottles of Gaviscon Liquid Antacid missing a safety warning on labels.

You may also be interested in...



US COVID-19 Warnings Continue Climbing, Violative Products Reach Recall Records

Additional products listed in FDA recall records update include Similac Pro-Advance Infant Formula filled with water, a lidocaine patch linked to potentially deficient manufacturing quality controls and two scents of PS Primer Water that may be contaminated. Number of hand sanitizer products exported from to the US and found containing methanol also continues to climb.

Like Health And Economic Impact, COVID-19 Unprecedented As Unlawful Claims Driver

Variety of products advertised with false coronavirus claims also grew in FTC's latest warnings submitted. It warned 21 firms on claims for products including IV drips, ozone therapy and stem cell treatments.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel